Skip to main content
AMRX
NASDAQ Life Sciences

Amneal Pharmaceuticals Reprices $2.08 Billion Term Loan, Expects $12M Annual Interest Savings

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$18.85
Mkt Cap
$6.019B
52W Low
$7.665
52W High
$19.26
52W Position info
146% above low
Off High info
2.1% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

AMRX has more than doubled off its 52-week low of $7.665.

Summary

Amneal Pharmaceuticals has successfully repriced its $2.08 billion term loan, reducing the interest rate margin by 50 basis points and expecting to save approximately $12 million in annualized cash interest expense.


Key Events · Financing and Capital Events · AMRX

  • Debt Repricing Completed

    Amneal Pharmaceuticals LLC, a subsidiary, entered into Amendment No. 3 to its Term Loan Credit Agreement, repricing approximately $2.084 billion in term loans.

  • Interest Rate Margin Reduced

    The applicable interest rate margin on the repriced term loans was reduced by 50 basis points (0.50%), to 1.50% for ABR Loans and 2.50% for Term Benchmark Loans.

  • Estimated Annual Interest Savings

    The company estimates this repricing will result in approximately $12 million in annualized cash interest expense savings.

  • Maturity Date Unchanged

    The stated maturity date of August 1, 2032, for the term loans remains unchanged.


Analysis · AMRX · Life Sciences

This 8-K reports a positive financial development for Amneal Pharmaceuticals. The company has repriced a significant portion of its term loan debt, lowering its interest rate margin. This move is expected to generate $12 million in annual cash interest savings, directly improving the company's profitability and cash flow. This action reflects a proactive approach to capital management and comes amidst a period of positive operational news, including recent FDA approvals and strong earnings.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMRX was trading at $18.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $7.67 to $19.26. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMRX - Latest Insights

AMRX
Nov 17, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $21.12
Real-time Price: $21.48 info
Change: +$0.360 (+2%) info
Market Cap: $7.489B info
AMRX
Nov 09, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.28
Real-time Price: $21.48 info
Change: +$0.200 (+0.94%) info
Market Cap: $7.489B info
AMRX
Nov 03, 2026, 6:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.23
Real-time Price: $21.48 info
Change: +$1.25 (+6%) info
Market Cap: $7.489B info
AMRX
Nov 03, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $20.20
Real-time Price: $21.48 info
Change: +$1.28 (+6%) info
Market Cap: $7.489B info
AMRX
Oct 23, 2026, 4:05 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $20.38
Real-time Price: $21.48 info
Change: +$1.10 (+5%) info
Market Cap: $7.489B info